<DOC>
	<DOCNO>NCT00253175</DOCNO>
	<brief_summary>The primary purpose study evaluate effectiveness safety topiramate ( epilepsy medication ) compare placebo prevention migraine .</brief_summary>
	<brief_title>A Study Effectiveness Safety Topiramate Prevention Migraine</brief_title>
	<detailed_description>Topiramate medication widely use treatment adult pediatric patient seizures show preliminary study effective migraine prevention adult . This outpatient , randomize , double-blind , placebo-controlled study confirm preliminary study effectiveness topiramate prevention migraine attack . The study compose 4 phase : pretreatment , double-blind treatment 20 week , blind transition , open-label extension . During pretreatment phase patient discontinue medication migraine prevention keep daily record headache information diary . Patients 3 8 migraine , 15 headache day , pretreatment phase continue double-blind treatment phase . In 20-week double-blind treatment phase , oral topiramate tablet ( placebo ) take daily begin 25 mg daily 1 week , increase twice daily dos maximum 8 tablet ( 200 mg ) per day 8-week titration period , maintain dose 12-week maintenance period . Patients successfully complete double-blind therapy phase may continue open-label extension ( 32 week ) , study medication ( topiramate placebo ) decrease simultaneously topiramate ( open-label ) administer increase dos . During study , patient maintain headache medication record document follow : occurrence duration headache ; severity headache pain ; associate symptom , nausea , vomit , photophobia ( avoidance dread light ) , phonophobia ( fear sound ) ; medication take relieve headache pain symptom . The primary measure effectiveness percent reduction frequency monthly migraine episode entire double-blind treatment phase compare pretreatment phase . Other assessment effectiveness include percent patient respond treatment ( &gt; = 50 % reduction average monthly migraine attack ) double-blind treatment phase compare pretreatment phase , reduction number migraine days/month treatment , reduction severity duration migraine treatment . Safety assessment include incidence adverse event throughout study , measurement vital sign ( pulse , blood pressure , body weight ) , physical examination , clinical laboratory test ( hematology , biochemistry , urinalysis ) specify interval . The study hypothesis decrease mean monthly migraine rate great topiramate group placebo group . Oral topiramate tablet 25 mg placebo tablet , begin 25 mg daily 1 week , increase twice daily dos maximum 8 tablet ( 200 mg ) 8-week titration period , maintain dose 12-week maintenance period ( 20 week total duration ) .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Vascular Headaches</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Meet criterion International Headache Society classification migraine without aura ( migraine symptom ) Diagnosis migraine least 12 month prior start study Have average 3 8 migraine attack per month 3 month prior start study Ability recognize migraine headache distinguish tensiontype headache type head pain General good health Patients previously fail respond topiramate therapy migraine prevention discontinue topiramate due adverse event Patients onset migraine age 50 Patients 15 headachedays per month 3 month prior start study , baseline ( pretreatment ) period Patients cluster headache exclusively aura ( migraine symptom ) without headache Female patient pregnant , nursing , use adequate birth control , capable bearing child</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>topiramate</keyword>
	<keyword>migraine headache</keyword>
	<keyword>migraine prevention</keyword>
	<keyword>migraine</keyword>
</DOC>